|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma显示文摘BACKGROUND Combined hepatocellular and cholangiocarcinoma(HCC/CC)is a rare primary hepatic malignancy which carries a poor prognosis due to its aggressive nature.Few centers have enough cases to draw definitive conclusions and there is limited understanding of prognosis.Given the rarity of HCC/CC,an analysis of large national cancer database was needed to obtain larger number of HCC/CC cases.AIM To identify associated factors for 5-year survival of HCC/CC.METHODS We conducted a retrospective study of The Surveillance,Epidemiology,and End Results(SEER)database obtained from SEER*Stat 8.3.6 software.Previously defined histology code 8180 for the International Classification of Disease for Oncology,3rd edition was used to identify HCC/CC cases from 2004 to 2015.We collected demographics,American Joint Committee on Cancer(AJCC)stage,treatment,tumor size,and survival data.These data were converted to categorical variables.The Shapiro-Wilk normality test was used to assess normal distribution.Mann-Whitney U test was used to compare continuous variables without normal distribution,and t-test was used to compare continuous variables with a normal distribution.The Kaplan-Meier survival curve analyzed 5-year survival.Univariate and multivariate logistic regression model was used to analyze factors associated with 5-year survival.Multivariate Cox proportional hazard regression was done on 5-year survival.We defined P<0.05 was statistically significant.RESULTS We identified 497 patients with the following characteristics:Mean age 62.4 years(SD:11.3),149(30.0%)were female,racial distribution was:276(55.5%)white,53(10.7%)black,84(16.9%)Asian and Pacific Islander(API),77(15.5%)Hispanic,and 7(1.4%)others or unknown.Stage I/II disease occurred in 41.5%and tumor size<50 mm was seen in 35.6%of patients.Twenty-four(4.8%)received locoregional therapy(LRT),119(23.9%)underwent resection,and 50(10.1%)underwent liver transplantation.The overall median survival was 6 mo[Interquartile range(IQR):1-22].After multivariate logistic regression,tumor size<50 mm[Odds ratios(OR):2.415,P=0.05],resection(OR:12.849,P<0.01),and transplant(OR:27.129,P<0.01)showed significance for 5-year survival.Age>60,sex,race,AJCC stages,metastasis,and LRT were not significant.However,API vs white showed significant OR of 2.793(CI:1.120-6.967).Cox proportional hazard regression showed AJCC stages,tumor size<50 mm,LRT,resection,and transplant showed significant hazard ratio.CONCLUSION HCC/CC patients with tumor size<50 mm,resection,and transplant were associated with an increase in 5-year survival.API showed advantageous OR and hazard ratios over white,black. | Tomoki Sempokuya Eric A Wien Robert J Pattison Jihyun Ma Linda L Wong | 2020 | World Journal of Hepatology2020，12，11： | 2 |
| 2 | Clonal heterogeneity in differentiation potential of immortalized human mesenchymal stem cells显示文摘 | Takeshi O Tomoki A Tomitaka N | 2002 | Biochem Biophys Res Commun2002，295，2： | 1 |
| 3 | Triterpene saponins and lignans from the roots of Pulsatilla chinensis and their cytotoxic activity against HL-60 cells 显示文摘 | Yoshihiro M Minpei K Tomoki A | 1999 | Nat Prod1999，62，： | 1 |
| 4 | Propene epoxidation with dioxygen catalyzed by gold clusters 显示文摘 | I-IUANG J HARUTA M TOMOKI A | 2009 | Angew Chem Int Ed2009，48，42： | 1 |
| 5 | Coherent addition of fiber lasers by use of a fiber coupler显示文摘 | SHIRAKAWA A TOMOKI Sekiguchi T S UEDA K I | 2002 | Optics Express2002，10，21： | 1 |
| 6 | Fabrication of silver patterns on polyimide films based on solid-phase electrchemical constructive lithography using ion- exchanged precursor layers 显示文摘 | KENSUKE A YURINA F TOMOKI T | 2011 | Langmuir2011，27，11： | 1 |
| 7 | Analysis of electrocatalyst degradation in PEMFC caused by cell reversal during fuel starvation显示文摘 | Akira T Tomoki A Kazuaki Y | 2004 | J Power Sources2004，130，12： | 1 |
| 8 | Efficient synthesis of o-alkynyl-N-pivaloyl anilines from o-acyl-N-pivaloylanilines and lithium trimethylsilyldiazomethane显示文摘 | Yoshiyuki H Tomoki K Toyohiko A | 2006 | Tetrahedron Letters2006，47，： | 1 |
| 9 | Analytical TEM Observation of Au Nano- particles on Cerium Oxide显示文摘 | Tomoki A Mitsutaka O Koji T | 2006 | Catalysis Today2006，117，13： | 1 |
| 10 | Febrile seizures associated with influenza A 显示文摘 | Keita H Takuya T Tomoki A | 2007 | Brain Develop2007，29，1： | 1 |
| 11 | Distribution of rutaceae-specific repeated sequences isolated from citrus genomea显示文摘 | Tomoki M Mitsuo O Tomoya A | 2001 | Annals of Botany2001，87，： | 1 |
| 12 | Impact of sarcopenia on mortality in patients undergoing liver retransplantation显示文摘BACKGROUND Sarcopenia,which is a loss of skeletal muscle mass,has been reported to increase post-transplant mortality and morbidity in patients undergoing the first liver transplant.Cross-sectional imaging modalities typically determine sarcopenia in patients with cirrhosis by measuring core abdominal musculatures.However,there is limited evidence for sarcopenia related outcomes in patients undergoing liver re-transplantation(re-OLT).AIM To evaluate the risk of mortality in patients with pre-existing sarcopenia following liver re-OLT.METHODS This is a retrospective study of all adult patients who had undergone a liver re-OLT at the University of Nebraska Medical Center from January 1,2007 to January 1,2017.We divided patients into sarcopenia and no sarcopenia groups.“TeraRecon AquariusNet 4.4.12.194”software was used to evaluate computed tomography or magnetic resonance imaging of the patients done within one year prior to their re-OLT,to calculate the Psoas muscle area at L3-L4 intervertebral disc.We defined cutoffs for sarcopenia as<1561 mm2 for males and<1464 mm2 for females.The primary outcome was to compare 90 d,one,and 5-year survival rates.We also compared complications after re-OLT,length of stay,and readmission within 30 d.Survival analysis was performed with Kaplan-Meier survival analysis.Continuous variables were evaluated with Wilcoxon rank-sum tests.Categorical variables were evaluated with Fisher’s exact tests.RESULTS Fifty-seven patients were included,32 males:25 females,median age 50 years.Two patients were excluded due to incomplete information.Overall,47%(26)of patients who underwent re-OLT had sarcopenia.Females were found to have significantly more sarcopenia than males(73%vs 17%,P<0.001).Median model for end stage liver disease at re-OLT was 28 in both sarcopenia and no sarcopenia groups.Patients in the no sarcopenia group had a trend of longer median time between the first and second transplant(36.5 mo vs 16.7 mo).Biological markers,outcome parameters,and survival at 90 d,1 and 5 years,were similar between the two groups.Sarcopenia in re-OLT at our center was noted to be twice as common(47%)as historically reported in patients undergoing primary liver transplantation.CONCLUSION Overall survival and outcome parameters were no different in those with and without the evidence of sarcopenia after re-OLT. | Amaninder Dhaliwal Diana Larson Molly Hiat Lyudmila M Muinov William L Harrison Harlan Sayles Tomoki Sempokuya Marco A Olivera Fedja A Rochling Timothy M McCashland | 2020 | World Journal of Hepatology2020，12，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员